eudract_number,eudract_number_with_country,meta_updated,date_of_the_global_end_of_the_trial,trial_is_part_of_a_paediatric_investigation_plan,end_of_trial_status,trial_status,trial_human_pharmacology_phase_i,trial_therapeutic_exploratory_phase_ii,trial_therapeutic_confirmatory_phase_iii,trial_therapeutic_use_phase_iv,trial_bioequivalence_study,subject_healthy_volunteers,trial_condition_being_studied_is_a_rare_disease,trial_single_blind,full_title,abbreviated_title,trial_results,sponsors,not_bioequivalence_study,rare_disease_blank,not_rare_disease,not_single_blind,not_healthy_volunteers,non_eu
2017-000830-68,2017-000830-68-CZ,2021-07-03 01:40:35.322631+01,,0,Completed,Completed,0,1,0,0,0,0,0,0,"A PHASE IB/II STUDY OF COBIMETINIB ADMINISTERED AS SINGLE AGENT AND IN COMBINATION WITH VENETOCLAX, WITH OR WITHOUT ATEZOLIZUMAB, IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA 
 
 
 Studie fáze IB/II hodnotící cobimetinib podávaný samostatně a v kombinaci s venetoclaxem, s atezolizumabem nebo bez atezolizumabu, u pacientů s relabujícím a refrakterním mnohočetným myelomem",,0,"[{'e_mail': 'global.rochegenentechtrials@roche.com', 'country': 'Switzerland', 'post_code': '4070', 'town_city': 'Basel', 'street_address': 'Grenzacherstrasse 124', 'name_of_sponsor': 'F. Hoffman-La Roche Ltd.', 'name_of_organisation': 'F.Hoffmann-La Roche Ltd.', 'status_of_the_sponsor': 'Commercial', 'functional_name_of_contact_point': 'Trial Information Support Line-TISL', 'name_of_organisation_providing_support': 'F. Hoffmann-La Roche Ltd.'}]",1,0,1,1,1,0
2012-001592-37,2012-001592-37-ES,2021-07-03 01:40:36.322631+01,2015-02-11,0,Completed,Completed,0,1,0,0,0,0,0,0,"Effect of 3-month treatment with F2695 (75mg OD) on improving functional recovery of patients with ischemic stroke. A Multicenter, Randomised, Double-blind, Parallel-group, Placebo-Controlled Study. 
 
 
 Efecto del tratamiento con F2695 (75 mg una vez al día) durante 3 meses en la mejoría de la recuperación funcional de pacientes con accidente cerebrovascular isquémico. Estudio multicéntrico, aleatorizado, doble ciego, en grupos paralelos y controlado con placebo","LIFE Study 
 
 
 Estudio LIFE",1,"[{'e_mail': 'mohammed.zaim@pierre-fabre.com', 'country': 'France', 'post_code': 'F-3103', 'town_city': 'TOULOUSE', 'fax_number': '+33-(0)5-34-50-62-20', 'street_address': 'BP 13562 - 3 avenue Hubert Curien', 'name_of_sponsor': 'Pierre Fabre Médicament; Represented by Institut de Recherche Pierre Fabre', 'telephone_number': '+33-(0)5-34-50-61-91', 'name_of_organisation': 'IRPF - Pierre Fabre Innovation', 'status_of_the_sponsor': 'Commercial', 'functional_name_of_contact_point': 'Dr Mohammed ZAÏM', 'name_of_organisation_providing_support': 'Pierre Fabre Médicament'}]",1,0,1,1,1,0
2012-000905-53,2012-000905-53-LV,2021-07-03 01:40:37.322631+01,2013-11-17,0,Completed,Completed,0,0,1,0,0,0,0,0,"A randomised, double blind, placebo controlled, parallel group efficacy and safety study of oral administration of empagliflozin twice daily versus once daily in two different daily doses over 16 weeks as add-on therapy to a twice daily dosing regimen of metformin in patients with type 2 diabetes mellitus and insufficient glycaemic control 
 
 
 Randomizēts, dubultmaskēts, placebo kontrolēts, paralēlu grupu efektivitātes un drošības pētījums, perorāli lietojot empagliflozīnu 16 nedēļas divreiz dienā pret vienreiz dienā divās dažādās dienas devās, pacientiem ar II tipa cukura diabētu un nepietiekamu glikēmisko kontroli kā papildus terapiju divas reizes dienā nozīmētai metformīna terapijai.",,1,"[{'e_mail': 'clintriage.rdg@boehringer-ingelheim.com', 'country': 'Germany', 'post_code': '55216', 'town_city': 'Ingelheim am Rhein', 'fax_number': '+498008217119', 'street_address': 'Binger Strasse 173', 'name_of_sponsor': 'Boehringer Ingelheim RCV GmbH & Co KG', 'telephone_number': '+498002430127', 'name_of_organisation': 'Boehringer Ingelheim Pharma GmbH & Co KG', 'status_of_the_sponsor': 'Commercial', 'functional_name_of_contact_point': 'QRPE PSC CT Information Disclosure', 'name_of_organisation_providing_support': 'Boehringer Ingelheim RCV GmbH & Co KG'}]",1,0,1,1,1,0
2008-000662-23,2008-000662-23-BE,2021-07-03 01:40:38.322631+01,2012-09-18,0,Completed,Completed,0,1,0,0,0,0,0,0,"A randomized, multicenter phase II study to explore whether biomarkers correlate with treatment outcome in chemo-naive patients with advanced or recurrent non-squamous non-small cell lung cancer, who receive treatment with bevacizumab (at a dose of either 7.5 mg/kg or 15 mg/kg) in addition to carboplatin based chemotherapy (gemcitabine or paclitaxel)",,1,"[{'country': 'Switzerland', 'name_of_sponsor': 'F. Hoffmann La-Roche Ltd', 'status_of_the_sponsor': 'Commercial'}]",1,0,1,1,1,0
2017-000830-68,2017-000830-68-NL,2021-06-03 01:40:35.322631+01,2021-05-18,0,Completed,Completed,0,1,0,0,0,0,0,1,"A PHASE IB/II STUDY OF COBIMETINIB ADMINISTERED AS SINGLE AGENT AND IN COMBINATION WITH VENETOCLAX, WITH OR WITHOUT ATEZOLIZUMAB, IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA",,0,"[{'e_mail': 'global.rochegenentechtrials@roche.com', 'country': 'Switzerland', 'post_code': '4070', 'town_city': 'Basel', 'street_address': 'Grenzacherstrasse 124', 'name_of_sponsor': 'F. Hoffman-La Roche Ltd.', 'name_of_organisation': 'F.Hoffmann-La Roche Ltd.', 'status_of_the_sponsor': 'Commercial', 'functional_name_of_contact_point': 'Trial Information Support Line-TISL', 'name_of_organisation_providing_support': 'F. Hoffmann-La Roche Ltd.'}]",1,0,1,0,1,0
